AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19065098 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based intervention for dementia caregivers, details on dosage and duration not available.
Number of subjects: 0
Study 19065098 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer program, details on dosage and duration not available.
Number of subjects: 0
Study 17068085 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) model - Model A
Number of subjects: 93
Study 17068085 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) model - Model B
Number of subjects: 93
Study 15307855 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (60 min total: 30 min running and 30 min resistance exercises)
Number of subjects: 20
Study 11558843 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral slow-release isosorbide dinitrate (ISDN) 20 mg three times a day
Number of subjects: 1102
Study 11558843 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 1102
Study 8822678 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults (55 years and older)
Number of subjects: 100
Study 8822678 — intervention group
Group type: COMPARATOR
Intervention: Younger adults (18 to 54 years old)
Number of subjects: 100
Study 1448251 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomeroy tubal ligation using endoloop sutures
Number of subjects: 53
Study 1448251 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic tubal ligation with Silastic rings
Number of subjects: 53
Study 3972221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileal infusion of Intralipid
Number of subjects: 5
Study 30803843 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated enterovirus A71 vaccine, administered in two doses with a 28-day or 56-day interval, booster dose at one year for participants aged two months to <two years
Number of subjects: 363
Study 30803843 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated enterovirus A71 vaccine
Number of subjects: 363
Study 30803843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study 29989868 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day of chelated zinc gluconate for one month
Number of subjects: 28
Study 29989868 — intervention group
Group type: COMPARATOR
Intervention: Control group (diet rich in zinc only)
Number of subjects: 28
Study 26645244 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional endoscopic sinus surgery (FESS) combined with septorhinoplasty (SRP)
Number of subjects: 55
Study 26645244 — intervention group
Group type: COMPARATOR
Intervention: Septorhinoplasty (SRP) alone
Number of subjects: 55
Study 24925492 — intervention group
Group type: EXPERIMENTAL
Intervention: TeenDrivingPlan (TDP)
Number of subjects: 151
Study 22805391 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg sublingual isosorbide dinitrate (ISDN)
Number of subjects: 60
Study 22805391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20824151 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 74
Study 20824151 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200 mg/day
Number of subjects: 74
Study 20824151 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Pravastatin and Fenofibrate) from weeks 12-48
Number of subjects: 74
Study 20824151 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 74
Study 17099309 — intervention group
Group type: EXPERIMENTAL
Intervention: Amuchina 10% solution
Number of subjects: 60
Study 17099309 — intervention group
Group type: COMPARATOR
Intervention: pH neutral soap
Number of subjects: 60
Study 16225577 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic model based on patient history, pelvic examination, and validated questionnaire
Number of subjects: 82
Study 16225577 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolapse of the posterior vaginal wall, history of abdominal or pelvic surgery, and presence of constipation
Number of subjects: 82
Study 12396323 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) 6 mg/kg
Number of subjects: 42
Study 12396323 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg
Number of subjects: 42
Study 12396323 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of DEC (6 mg/kg) and Albendazole (400 mg)
Number of subjects: 42
Study 12396323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 10546012 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-abdominal fat
Number of subjects: 175
Study 10546012 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose
Number of subjects: 175
Study 10546012 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-h glucose
Number of subjects: 175
Study 10546012 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting HDL cholesterol
Number of subjects: 175
Study 10546012 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting HDL2 cholesterol
Number of subjects: 175
Study 10546012 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting HDL3 cholesterol
Number of subjects: 175
Study 10546012 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting triglycerides
Number of subjects: 175
Study 10546012 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 175
Study 10546012 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 175
Study 10546012 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of diabetes
Number of subjects: 175
Study 7597431 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 170 mg/m2 followed by ifosfamide 5 g/m2 divided over 3 days with mesna
Number of subjects: 13
Study 7597431 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/5-fluorouracil
Number of subjects: 13
Study 2142040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 18
Study 2142040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 724875 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive therapy
Number of subjects: 42
Study 724875 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretative therapy
Number of subjects: 42
Study 724875 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (control)
Number of subjects: 42
Study 29217959 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% lemongrass oil mouthwash
Number of subjects: 45
Study 29217959 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthwash
Number of subjects: 45
Study 29217959 — intervention group
Group type: COMPARATOR
Intervention: Oral prophylaxis only
Number of subjects: 45
Study 26031786 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical alert device
Number of subjects: 265
Study 26031786 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 265
Study 23930635 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive Adper Prompt L-Pop
Number of subjects: 45
Study 23930635 — intervention group
Group type: COMPARATOR
Intervention: Conventional phosphoric acid-etching technique
Number of subjects: 45
Study 23930635 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (self-etching and conventional)
Number of subjects: 45
Study 21285943 — intervention group
Group type: EXPERIMENTAL
Intervention: Group treatment (15 sessions separately for children and parents)
Number of subjects: 0
Study 21285943 — intervention group
Group type: COMPARATOR
Intervention: Routine counselling (two appointments for children)
Number of subjects: 0
Study 18811602 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of isotretinoin thrice a week for 3 months
Number of subjects: 30
Study 18811602 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of isotretinoin thrice a week for 3 months
Number of subjects: 30
Study 18811602 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg and 20 mg of isotretinoin
Number of subjects: 30
Study 17350990 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir + saquinavir (400/100 mg + 800 mg)
Number of subjects: 30
Study 17350990 — intervention group
Group type: COMPARATOR
Intervention: lopinavir/ritonavir + zidovudine/lamivudine (400/100 mg + 150/300 mg)
Number of subjects: 30
Study 17350990 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir + saquinavir (600 or 800 mg)
Number of subjects: 30
Study 17350990 — intervention group
Group type: COMPARATOR
Intervention: lopinavir/ritonavir + zidovudine/lamivudine
Number of subjects: 30
Study 14705221 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive cholesterol lowering dietary program
Number of subjects: 17
Study 14705221 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17
Study 11883998 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (13 IU/m(2) for 4 days) + glutamine-free TPN
Number of subjects: 31
Study 11883998 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (13 IU/m(2) for 4 days) + glutamine-enriched TPN (7 g GLN/m(2)/day)
Number of subjects: 31
Study 11883998 — intervention group
Group type: COMPARATOR
Intervention: Glutamine-enriched TPN (without rhGH)
Number of subjects: 31
Study 11883998 — intervention group
Group type: EXPERIMENTAL
Intervention: GH treated groups
Number of subjects: 31
Study 11883998 — intervention group
Group type: COMPARATOR
Intervention: Group III (glutamine-enriched TPN without rhGH)
Number of subjects: 31
Study 9630144 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed endurance and calisthenic/strength activities performed at a rapid pace three times weekly for 12 weeks
Number of subjects: 20
Study 8166318 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light therapy (10,000 lux for 30 min/day)
Number of subjects: 17
Study 8166318 — intervention group
Group type: COMPARATOR
Intervention: Dim red light therapy (500 lux for 30 min/day)
Number of subjects: 17
Study 8166318 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light therapy (10,000 lux for 30 min/day) in patients with seasonal bulimia
Number of subjects: 17
Study 8166318 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light therapy (10,000 lux for 30 min/day) in patients with nonseasonal bulimia
Number of subjects: 17
Study 3284292 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (12.5‐25 mg b.d.)
Number of subjects: 16
Study 3284292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29514268 — intervention group
Group type: EXPERIMENTAL
Intervention: TARGET workshop
Number of subjects: 152
Study 28537969 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% (levo group)
Number of subjects: 19
Study 28537969 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% solution (saline group)
Number of subjects: 19
Study 28537969 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (levo vs saline)
Number of subjects: 19
Study 26625505 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-payment reduction from $8 to $0 per medication per month for antihypertensive prescriptions
Number of subjects: 479
Study 26625505 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized behavioral intervention (CBI)
Number of subjects: 479
Study 26625505 — intervention group
Group type: EXPERIMENTAL
Intervention: Both co-pay reduction and CBI
Number of subjects: 479
Study 26625505 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 479
Study 23445666 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced Auditory Serial Addition Test (PASAT)
Number of subjects: 22
Study 23445666 — intervention group
Group type: COMPARATOR
Intervention: Classical music (neutral intervention)
Number of subjects: 22
Study 20875370 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 900 mg
Number of subjects: 36
Study 20875370 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 36
Study 20875370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 18172233 — intervention group
Group type: EXPERIMENTAL
Intervention: Using magnification loupes
Number of subjects: 35
Study 18172233 — intervention group
Group type: EXPERIMENTAL
Intervention: Using magnification loupes immediately on entering the program
Number of subjects: 35
Study 18172233 — intervention group
Group type: COMPARATOR
Intervention: Not using magnification loupes
Number of subjects: 35
Study 15690268 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 20 microg mixed with hyperbaric ropivacaine 10 mg (group FR10)
Number of subjects: 60
Study 15690268 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric ropivacaine 15 mg (group R15)
Number of subjects: 60
Study 12753258 — intervention group
Group type: EXPERIMENTAL
Intervention: COLIA1 polymorphism (specifically the 'ss' genotype)
Number of subjects: 156
Study 12753258 — intervention group
Group type: EXPERIMENTAL
Intervention: Utilization of haplotypes of VDR gene polymorphisms
Number of subjects: 156
Study 12753258 — intervention group
Group type: COMPARATOR
Intervention: VDR gene polymorphisms
Number of subjects: 156
Study 10569649 — intervention group
Group type: EXPERIMENTAL
Intervention: TNK-tPA 30 mg
Number of subjects: 886
Study 10569649 — intervention group
Group type: EXPERIMENTAL
Intervention: TNK-tPA 40 mg
Number of subjects: 886
Study 10569649 — intervention group
Group type: EXPERIMENTAL
Intervention: TNK-tPA 50 mg
Number of subjects: 886
Study 10569649 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-dose tertile (0.40 to 0.51 mg/kg)
Number of subjects: 886
Study 10569649 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tertile (0.52 to 1.24 mg/kg)
Number of subjects: 886
Study 10569649 — intervention group
Group type: COMPARATOR
Intervention: Low-dose tertile (0.2 to 0.39 mg/kg)
Number of subjects: 886
Study 10569649 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose and mid-dose tertiles
Number of subjects: 886
Study 8947402 — intervention group
Group type: EXPERIMENTAL
Intervention: Power squat
Number of subjects: 0
Study 8947402 — intervention group
Group type: EXPERIMENTAL
Intervention: Front squat
Number of subjects: 0
Study 8947402 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunge
Number of subjects: 0
Study 1844195 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological monitoring (cervical mucus) for HCG administration
Number of subjects: 0
Study 1844195 — intervention group
Group type: COMPARATOR
Intervention: Biochemical monitoring for HCG administration
Number of subjects: 0
Study 6996111 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplement (15 mg folic acid per day for 5 weeks)
Number of subjects: 5
Study 6996111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31826931 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF inhibitors
Number of subjects: 0
Study 31826931 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BRAF inhibition and TP53 reactivation
Number of subjects: 0
Study 31826931 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-specific mutation–drug associations
Number of subjects: 0
Study 31188881 — intervention group
Group type: EXPERIMENTAL
Intervention: Axiological-Identitary Collective Action Model (AICAM)
Number of subjects: 1138
Study 31188881 — intervention group
Group type: COMPARATOR
Intervention: Alternative models (including SIMCA)
Number of subjects: 1138
Study 28975664 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide q24h (median dose = 0.24 mg/kg/d; range = 0.10–0.69 mg/kg/d)
Number of subjects: 366
Study 28975664 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 366
Study 28975664 — intervention group
Group type: COMPARATOR
Intervention: Furosemide q12h (median dose = 1.39 mg/kg q12h; range = 0.70–6.30 mg/kg q12h)
Number of subjects: 366
Study 26695795 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment for type A SSNHL (acute in low tone frequencies) with FEF
Number of subjects: 1024
Study 26695795 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment for type B SSNHL (acute in high tone frequencies) with FEF
Number of subjects: 1024
Study 26695795 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment for type C SSNHL (acute in all frequencies) with FEF
Number of subjects: 1024
Study 26695795 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment for type D SSNHL (total deafness) with FEF
Number of subjects: 1024
Study 26695795 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment for type A SSNHL without FEF
Number of subjects: 1024
Study 26695795 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment for type B SSNHL without FEF
Number of subjects: 1024
Study 26695795 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment for type C SSNHL without FEF
Number of subjects: 1024
Study 26695795 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment for type D SSNHL without FEF
Number of subjects: 1024
Study 23995661 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally disintegrating tablets (ODTs)
Number of subjects: 10
Study 23995661 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro disintegration time measured using Tricorptester
Number of subjects: 10
Study 23995661 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between in vitro and clinical disintegration times
Number of subjects: 10
Study 21411411 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Glechoma hederacea extract lotion applied topically for 8 weeks
Number of subjects: 0
Study 21411411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19153829 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus capecitabine (L + C)
Number of subjects: 0
Study 19153829 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone (C)
Number of subjects: 0
Study 16454975 — intervention group
Group type: EXPERIMENTAL
Intervention: XS0601
Number of subjects: 335
Study 15181129 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 1 or 2 collaterals (Group I)
Number of subjects: 56
Study 15181129 — intervention group
Group type: COMPARATOR
Intervention: Grade 3 collaterals (Group II)
Number of subjects: 56
Study 15181129 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 56
Study 11402116 — intervention group
Group type: EXPERIMENTAL
Intervention: Local methylprednisolone injection (15 mg)
Number of subjects: 0
Study 11402116 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (low-dose, short-term)
Number of subjects: 0
Study 9248031 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-facepiece masks with clouded lenses
Number of subjects: 10
Study 9248031 — intervention group
Group type: COMPARATOR
Intervention: Pre-exercise visual acuity
Number of subjects: 10
Study 8392263 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic measurement of fetal biparietal diameter (BPD)
Number of subjects: 1713
Study 8392263 — intervention group
Group type: COMPARATOR
Intervention: Last menstrual period (LMP)
Number of subjects: 1713
Study 8392263 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of EDDs calculated from BPD and LMP
Number of subjects: 1713
Study 3525866 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol (1 mg. 3 times daily)
Number of subjects: 227
Study 3525866 — intervention group
Group type: COMPARATOR
Intervention: Estramustine phosphate (280 mg. twice daily for 8 weeks and 140 mg. twice daily thereafter)
Number of subjects: 227
Study 3525866 — intervention group
Group type: COMPARATOR
Intervention: Estramustine phosphate
Number of subjects: 227
Study 30304120 — intervention group
Group type: EXPERIMENTAL
Intervention: One implant (GI)
Number of subjects: 21
Study 30304120 — intervention group
Group type: EXPERIMENTAL
Intervention: Two implants (GII)
Number of subjects: 21
Study 27014909 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine and oxaliplatin with radiotherapy (Capox‐RT group)
Number of subjects: 0
Study 27014909 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine with radiotherapy (Cap‐RT group)
Number of subjects: 0
Study 24368436 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g LNS/d
Number of subjects: 376
Study 24368436 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g LNS/d
Number of subjects: 376
Study 24368436 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g LNS/d
Number of subjects: 376
Study 24368436 — intervention group
Group type: COMPARATOR
Intervention: No LNS (Control)
Number of subjects: 376
Study 22311634 — intervention group
Group type: EXPERIMENTAL
Intervention: ChitoHem(®) powder
Number of subjects: 124
Study 22311634 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemostatic procedure
Number of subjects: 124
Study 20371746 — intervention group
Group type: COMPARATOR
Intervention: <200 kcal/week of leisure-time physical activity
Number of subjects: 39315
Study 20371746 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 to 599 kcal/week of leisure-time physical activity
Number of subjects: 39315
Study 20371746 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 to 1499 kcal/week of leisure-time physical activity
Number of subjects: 39315
Study 20371746 — intervention group
Group type: EXPERIMENTAL
Intervention: > or =1500 kcal/week of leisure-time physical activity
Number of subjects: 39315
Study 20371746 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous physical activity
Number of subjects: 39315
Study 20371746 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking time and walking pace
Number of subjects: 39315
Study 16648508 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (5 mg every 2 hours as needed, maximum of four capsules a day for 7 days)
Number of subjects: 112
Study 16648508 — intervention group
Group type: COMPARATOR
Intervention: Placebo (every 2 hours as needed, maximum of four capsules a day for 7 days)
Number of subjects: 112
Study 16249975 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg/day, p.o.
Number of subjects: 10
Study 16249975 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg/day, p.o. + famotidine 40 mg/day, p.o.
Number of subjects: 10
Study 16249975 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole treatment (before treatment)
Number of subjects: 10
Study 16249975 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (before treatment)
Number of subjects: 10